Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 DSM BioSolutions To Manufacture PolyTherics Biologic | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

DSM BioSolutions To Manufacture PolyTherics Biologic

DSM BioSolutions, DSM’s microbial fermentation CMO business unit, and PolyTherics Ltd. have entered into an agreement for the process development and manufacture of PolyTherics’ lead “biobetter” product, HiPEG IFN α-2a.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

DSM BioSolutions, DSM’s microbial fermentation CMO business unit, and PolyTherics Ltd. have entered into an agreement for the process development and manufacture of PolyTherics’ lead “biobetter” product, HiPEG IFN α-2a. Financial terms were not disclosed.

PolyTherics applied its HiPEG site-specific PEGylation technology to interferon alpha to produce HiPEG IFN α-2a, which in a preclinical study showed eight-fold higher activity than a marketed PEGylated interferon in vitro, and a comparable half-life. PolyTherics is seeking partners for the development of HiPEG IFN α-2a for hepatitis C.

DSM has successfully started development, scale-up and manufacture of the recombinant his-tagged IFN α-2a. PolyTherics will transfer its HiPEG PEGylation method to DSM for scale-up. The companies plan to develop a process to produce sufficient material for preclinical and clinical development.

Keith Powell, chief executive officer of PolyTherics, said, “The transfer of the production of our lead product to a contract manufacturer is a major milestone for PolyTherics and is the beginning of the development stage of its first biobetter drug.”

Villaume Kal, vice president of DSM BioSolutions said, “We are delighted to work with PolyTherics on this promising biobetter compound. Our technology, operational excellence, and outstanding cGMP and compliance record with the EMA and FDA allows us to serve this important customer and to develop, scale-up and manufacture their preclinical and clinical material.”

Visit DSM at Contract Pharma’s Contracting & Outsourcing Conference on September 23rd!

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics